Redsense Medical AB ("Redsense" or the "Company") has become aware that one of the Company's shareholders, Discover Capital GmbH (registered in the Company's share register as Axxion S.A), has acquired 250,000 shares in Redsense and thus reached above the level of 5 percent of the total number of registered shares and votes in the Company. Discover Capital GmbH's holdings after the transaction amounts to a total of 750,000 shares, corresponding to approximately 5.34 percent of the votes and capital in Redsense.

For additional information, please contact:

Patrik Byhmer
CEO Redsense Medical AB (publ)

Phone: +46 (0) 35 - 10 60 30
E-mail: patrik.byhmer@redsensemedical.com
Website: www.redsensemedical.com

ABOUT REDSENSE MEDICAL

Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovation used for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector.